Back To Search Instructions
Protocols
12 protocols meet the specified criteria
Disease Site: Non-Hodgkin's Lymphoma
Protocol No.TitleStatus
0500000226Arizona Lymphoid Tissue and Blood Repository (ALTBR)Open
0900000967Lymphoma Outcomes and Epidemiological DatabaseOpen
1100000610A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications (10-CBA)Open
1507953455Phase II study of Brentuximab Vedotin in Combination with Bendamustine and Rituximab, in patients with CD30 Positive, Relapsed or refractory B Cell Non-Hodgkin's Lymphoma (NHL)Open
1602386062A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Venetoclax in Patients with Relapsed or Refractory Follicular or Diffuse Large B-Cell LymphomaOpen
1603472947Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients with Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaOpen
1606616633Phase Ib Trial of Pembrolizumab (MK-3475) in Combination with Dinaciclib (MK-7965) in Subjects with Hematologic Malignancies (KEYNOTE-155)Open
1606619215An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast CancerOpen
1607710095Impact of stem cell transplantation in first complete remission for patients with double hit lymphomaOpen
1607750810A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Previously Treated B-Cell Malignancies (INCB50465-101)Open
1609876907A Phase I/II Study of Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide and/or BendamustineOpen
1612098443An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize theEffects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects with B-cell LymphomasOpen